Lineage Cell Therapeutics, Inc. (FRA:BT3)

Market Cap	244.89M +4.8%
Revenue (ttm)	11.45M +19.9%
Net Income	-28.24M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.9410
Previous Close	0.9110
Day's Range	0.9410 - 0.9410
52-Week Range	0.8820 - 1.6800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 75
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BT3

Financial Performance

In 2025, Lineage Cell Therapeutics's revenue was $14.56 million, an increase of 53.24% compared to the previous year's $9.50 million. Losses were -$63.53 million, 241.4% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error